Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Новый представитель класса статинов – крестор: возможности в лечении больных с метаболическим синдромом
Новый представитель класса статинов – крестор: возможности в лечении больных с метаболическим синдромом
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81: 66B–69B.
2. Goldschmidt MG, Barret-Conner E, Edelstein SL et al. Dyslipidaemia and ischaemic heart disease mortality among men and women with diabetes. Circulation 1994; 89: 991–7.
3. Scandinavian Simvastatin Survival Study Group: Randomaised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
4. Appel S, Rufenacht T. Lack of Interaction Between Fluvastatin and Oral Hypoglycemia Agents in Healthy Subjects and in Patients with Non-Insulin-Dependent Diabetes Mellitus. Am J Cardiol 1995; 76: 29A–32A.
5. Rackley CE. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996; 19: 683–9.
6. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B–12B.
7. Jones P, Davidson M, Stein E et al. Comparison of efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 557–66.
8. Schuster H, Fox JC. Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004; 5 (5): 1187–200.
9. Balantyne CM, Stein EA, Paoletti R et al. Efficacy of Rosuvastatin 10 mg in patients with the Metabolic Syndrome. Am J Cardiol 2003; 91 (suppl.): 25C–28C.
10. Schuster H, Barter PJ, Stender S et al. For the MERCURY I study group: Effects of switching statins on achievement of lipid goal: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart Journal 2004; 147: 705–12.
2. Goldschmidt MG, Barret-Conner E, Edelstein SL et al. Dyslipidaemia and ischaemic heart disease mortality among men and women with diabetes. Circulation 1994; 89: 991–7.
3. Scandinavian Simvastatin Survival Study Group: Randomaised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
4. Appel S, Rufenacht T. Lack of Interaction Between Fluvastatin and Oral Hypoglycemia Agents in Healthy Subjects and in Patients with Non-Insulin-Dependent Diabetes Mellitus. Am J Cardiol 1995; 76: 29A–32A.
5. Rackley CE. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996; 19: 683–9.
6. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B–12B.
7. Jones P, Davidson M, Stein E et al. Comparison of efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 557–66.
8. Schuster H, Fox JC. Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004; 5 (5): 1187–200.
9. Balantyne CM, Stein EA, Paoletti R et al. Efficacy of Rosuvastatin 10 mg in patients with the Metabolic Syndrome. Am J Cardiol 2003; 91 (suppl.): 25C–28C.
10. Schuster H, Barter PJ, Stender S et al. For the MERCURY I study group: Effects of switching statins on achievement of lipid goal: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart Journal 2004; 147: 705–12.
Авторы
И.Е.Чазова, В.Б.Мычка, К.М.Мамырбаева, В.П.Масенко, Н.В.Флегонтова, В.Б.Сергиенко
Российский кардиологический научно-производственный комплекс Росздрава,
Институт кардиологии им. А.Л.Мясникова, Москва
Российский кардиологический научно-производственный комплекс Росздрава,
Институт кардиологии им. А.Л.Мясникова, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.